“Adamis announced FDA approval of Symjepi Jr. (15 mg) for treatment of anaphylaxis in pediatric patients. With both strengths of Symjepi now approved, we expect commercial partner Sandoz (Novartis, NVS – NR) to launch the EpiPen alternative, potentially in 4Q18.”
According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 18.8% and a 56.2% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
Adamis Pharma has an analyst consensus of Strong Buy, with a price target consensus of $9, which is a 130.8% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $7 price target.
The company has a one-year high of $5.85 and a one-year low of $2.20. Currently, Adamis Pharma has an average volume of 1.11M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Adamis Pharmaceuticals Corp. is a biopharmaceutical company which is focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy.. Its activities include the combination of pharmaceuticals and biotechnology to produce medicines for patients, and physicians.
Read More on ADMP: